leadf
logo-loader
RNS
viewAllergan

Citadel Group - Form 8.3 - Allergan plc

RNS Number : 2836G
Citadel Group
16 March 2020
 
























 

Ap 19

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.         KEY INFORMATION


























Name of person dealing (Note 1)

Citadel Group

Company dealt in

ALLERGAN PLC

Class of relevant security to which the dealings being disclosed relate (Note 2)

Common Stock ISIN IE00BY9D5467

Date of dealing

13 March, 2020

























2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security

                    dealt in (Note 3)









Long

Short

Common Stock  ISIN  IE00BY9D5467

Number        (%)

Number      (%)

(1) Relevant securities

1,510,609 (0.46%)

1,997 (0.00%)

(2) Derivatives (other than options)

3,465,201 (1.05%)

0 (0.00%)

(3) Options and agreements to purchase/sell

0 (0.00%)

0 (0.00%)

Total

4,975,810(1.51%)

1,997 (0.00%)



























 

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

























Long

Short


Number        (%)

Number      (%)

(1) Relevant securities



(2) Derivatives (other than options)



(3) Options and agreements to purchase/sell



Total































Ap 20






























1.         DEALINGS (Note 4)

 

(a)        Purchases and sales





























Purchase/sale

Common Stock ISIN IE00BY9D5467

Number of securities

Price per unit (Note 5)

82

180.17  USD

838

180.86192124  USD

563

180.86564831  USD

3,902

180.94262173  USD

358

180.98418994  USD

4,551

181.00061745  USD

20

181.13  USD

967

181.41404343  USD

200

181.475  USD

41

181.53  USD

100,000

181.636812  USD

934

181.75635974  USD

1,897

181.78796521  USD

1,542

181.80674449  USD

276

181.96884058  USD

200

182.09  USD

356

182.27589888  USD

2,865

182.28760558  USD

55

182.72272727  USD

9

183.06  USD

1,520

183.85  USD

-100

179.425  USD

-100

179.75  USD

-75

179.76  USD

-528

180.11772727  USD

-946

180.21680761  USD

-10

180.27  USD

-2,800

180.47107143  USD

-111

180.58036036  USD

-278

180.6773741  USD

-23

180.71347826  USD

-86

180.73953488  USD

-10

180.99  USD

-335

181.15985075  USD

-533

181.21348968  USD

-95

181.22  USD

-491

181.29533605  USD

-1,609

181.3033872  USD

-662

181.32637462  USD

-100

181.36  USD

-100

181.97  USD

-152

181.97881579  USD

-321

182.09760125  USD

-642

182.1582866  USD

-201

182.18965174  USD

-2,501

182.19010396  USD

-575

182.19652174  USD

-1,038

182.22359345  USD

-180

182.27555556  USD

-888

182.56643018  USD

-932

182.72993562  USD

-5

182.79  USD

-101

182.87158416  USD

-387

183.02855297  USD

-100

183.05  USD

-200

183.205  USD

-200

183.345  USD





















(b)        Derivatives transactions (other than options transactions)























Product name,

e.g. CFD

 ISIN

Nature of transaction

(Note 6)

 

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

























(c)        Options transactions in respect of existing relevant securities

 

(i)         Writing, selling, purchasing or varying























Product name, e.g. call option

Writing, selling, purchasing,

varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type,

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(Note 5)



























(ii)        Exercising
























Product name,

e.g. call option

Number of securities

Exercise price per unit

(Note 5)






























(d)        Other dealings (including transactions in respect of new securities) (Note 4)




























Nature of transaction

(Note 8)

      Details

      Price per unit

      (if applicable) (Note 5)







 



















Ap 21

















2.         OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 
















Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated

None














Is a Supplemental Form 8 attached? (Note 9)


NO

















 Date of disclosure:

16 March, 2020

 Contact name:

Pauline Rogers

 Telephone number:

020 7645 9700

If a connected EFM, name of offeree/offeror with which connected

n/a

If a connected EFM, state nature of connection (Note 10)

n/a





 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEBBGDXLSBDGGL

Quick facts: Allergan

Price: -

Market: NYSE
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

17 min read